Study associates accelerated biological aging with increased retinal drusen burden
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier C · Tier ceiling 74 · LONGIFI_SIGNAL_V1
Quick take
A cross-sectional cohort study of 5,322 participants established that accelerated biological aging is significantly associated with an increased burden of retinal drusen, suggesting that early structural signs of age-related macular degeneration reflect systemic aging processes.
What happened
A cross-sectional study published in Acta Ophthalmologica evaluated the relationship between accelerated biological aging and early or intermediate features of age-related macular degeneration (AMD) using a population-based cohort of 5,322 participants from the National Health and Nutrition Examination Survey (mean age 59.4 years; 50.4% female).
Biological age was calculated using the PhenoAge algorithm, a composite of chronological age and routine blood biomarkers, with PhenoAge Acceleration (PhenoAgeAccel) defined as the residual deviation.
A PhenoAgeAccel of more than 3 years was associated with significantly higher odds of having large drusen of 500 μm or greater (OR: 1.56, 95% CI: 1.07–2.27, p = 0.022) and intermediate drusen of 125 μm or greater (OR: 1.29, 95% CI: 1.00–1.65, p = 0.049).
No statistically significant association was observed between accelerated biological aging and pigmentary abnormalities.
Each one-year increase in PhenoAgeAccel was associated with a 2% increase in the odds of having large drusen (OR: 1.02, 95% CI: 1.00–1.04, p = 0.022).
Why it matters
The findings suggest that early and intermediate structural markers of macular degeneration are not solely isolated ocular anomalies but rather localized manifestations of systemic biological aging.
By establishing a correlation between systemic PhenoAge metrics and specific retinal pathology, the study reinforces the potential of systemic biological age clocks to track, predict, and characterize localized age-related tissue degradation.
Market impact
The confirmation that systemic aging correlates with localized drusen burden provides therapeutic validation for developers utilizing systemic or multi-pathway approaches to target ocular senescence and age-related retinal diseases.
Ophthalmic pipelines addressing advanced AMD phenotypes, such as geographic atrophy in dry age-related macular degeneration, may benefit from integrating systemic biological age indicators as valuable patient-selection or predictive biomarker endpoints.
What comes next
Whether clinical trials targeting systemic aging pathways, such as metabolic or epigenetic therapies, will evaluate changes in retinal drusen burden as secondary or exploratory biomarkers of therapeutic efficacy.
Sources
- NCBIPUBMED:LONGEVITY_RESEARCH